Approximately One Year Post-Launch, AbbVie’s Rinvoq Boasts Increasingly Favorable Perceptions Among Gastroenterologists for the Treatment of Ulcerative Colitis, According to Spherix Global Insights
Recent research suggests AbbVie has managed gastroenterologists’ concerns regarding JAK safety, setting up a potentially favorable encore in the Crohn’s disease market. EXTON, Pa., May 17, 2023 /PRNewswire/ — In March of 2022, the FDA approved AbbVie’s JAK1 inhibitor, Rinvoq (upadacitinib), for the treatment of moderate to severe ulcerative colitis (UC). Of note, however, JAK […]
Over Three Years After Receiving a Complete Response Letter From the FDA, Takeda’s Subcutaneous Formulation of Entyvio (Entyvio SC) is Poised to Enter a Rapidly Evolving UC Market, According to Spherix Global Insights
An FDA approval for Entyvio SC could exacerbate an already aggressive fight for second-line UC treatments. Exton, PA., May 4, 2023 – In December 2019, Takeda Pharmaceutical Company (“Takeda”) announced the receipt of a complete response letter (CRL) for the subcutaneous (SC) formulation of its successful ulcerative colitis (UC) treatment, Entyvio (vedolizumab). The intravenous (IV) […]
New Spherix Data in Alzheimer’s Disease Reveals High Potential for Emerging Anti-Amyloid Therapies from Genentech, Biogen/Eisai, and Eli Lilly, As Well As Novo Nordisk’s Semaglutide
New Spherix Data in Alzheimer’s Disease Reveals High Potential for Emerging Anti-Amyloid Therapies from Genentech, Biogen/Eisai, and Eli Lilly, As Well As Novo Nordisk’s Semaglutide Differentiation amongst these pipeline agents will hinge on ease of access, easy-to-use companion diagnostics, and safety EXTON, Pa., July 2022 – Despite multiple high-profile trial failures in early Alzheimer’s disease […]
Diabetes-Related Mechanisms of Action Make Their Move as Several NAFLD/NASH Pipeline Therapies Inch Closer to the First-Ever FDA Approval
Ten NAFLD/NASH pipeline product profiles were evaluated by US gastroenterologists and hepatologists to assess strengths, weaknesses, and physician receptivity EXTON, Pa., June 1, 2022 /PRNewswire/ — Spherix recently surveyed 103 US gastroenterologists and 20 hepatologists, along with conducting eight qualitative interviews (including 2 KOLs and 6 clinical trial participants), to assess the current and future management of […]
Betting on ‘Golden Age’ of Colonoscopies, Investors Buy Up Gastroenterology Practices
In 2021, the number of private equity acquisitions of gastroenterology practices grew by 28% over the previous year, according to Spherix Global Insights and Fraser Healthcare. Complex government regulations, technological innovations, and insurance industry practices have driven many gastroenterologists to sell shares in their practices, said Praveen Suthrum, who runs a consulting company for physician […]
Eylea Keeps its Lead In the Retinal Space as Physicians Remain Hesitant on Roche’s Susvimo — Report
Roche trumpeted a “major advancement” in the retinal space with the approval of its eye drug Susvimo last October, touting it as a more manageable option for patients with wet age-related macular degeneration. However, safety concerns leave some physicians hesitant. While most ophthalmologists have heard of Susvimo — 86%, according to the latest Spherix survey […]
Spherix Global Insights Finds US Primary Biliary Cholangitis Market Poised for Transformation as Pipeline Therapies Progress in Clinical Development
Four pipeline product profiles were evaluated by US gastroenterologists to assess strengths, weaknesses, and physician receptivity EXTON, Pa., March 16, 2022 /PRNewswire/ — Spherix recently surveyed 107 US gastroenterologists and conducted ten qualitative interviews (including a key opinion leader and six clinical trial participants) to assess the current and future management of primary biliary cholangitis (PBC). The […]
Gastroenterologists Report Challenges Treating Eosinophilic Esophagitis as New Therapies Inch Closer to FDA Approval
A high percentage of undiagnosed patients and difficulties with treatment adherence among this mostly younger male patient population could be addressed by the entrance of one or more FDA-approved therapies in the next year EXTON, Pa., November 16, 2021 /PRNewswire/ — Spherix recently surveyed 101 US gastroenterologists and followed up with ten qualitative interviews (including four with […]
Increased Biosimilar Prescribing and New Subcutaneous Formulations Are Poised to Impact Biologic Switching in the EU Inflammatory Bowel Disease Market, According to Spherix Global Insights
Infliximab and adalimumab biosimilars continue to increase their presence in ulcerative colitis and Crohn’s disease therapy switching, while Entyvio SC and Remsima SC will cannibalize prescribing of their intravenous formulations EXTON, Pa., November 9, 2020 /PRNewswire/ — According to the latest report published as part of Spherix’s RealWorld Dynamix™: Biologic/Small Molecule Switching in IBD (EU) service, EU gastroenterologists […]
COVID-19 Wreaking Havoc in Specialty Practices and the Vast Majority of Physicians Expect It to Get Worse in the Next Two Weeks, According to a New Report by Spherix Global Insights
Results from a survey of more than 300 dermatologists, gastroenterologists, nephrologists, neurologists, rheumatologists, and primary care physicians indicate a marked decrease in patient visits, growing concern over financial impact to practices, and worry over preparedness for a widespread local outbreak EXTON, Pa., March 24, 2020 / PRNewswire / – Spherix Global Insights is an independent […]
